

Influenza Therapeutic Landscape

Phase 1

Phase 2

Phase 3

Market

Viral Targets

Host Targets

Fab'entech
Equine
Polyclonal H5

SAREPTA THERAPEUTICS
Radavirsen

ZSP1273

FEBICO 遠東生技
Apomivir

Crucell
CR6261
mAb Grp 1

CELLTRION
CT-P27
2 mAbs

FUJIFILM
Favipiravir

The University of Hong Kong
Flufenamic
acid (FFA)

**Autoimmune
Technologies**
Flufvitide-3
HA inhibitor

**以岭药业
YILING PHARMACEUTICAL**
KT07
herb mix

**National Institute
of Allergy and
Infectious Diseases**
High titer
influenza
immune plasma

M2 Inhibitors
Forest Pharmaceuticals, Inc.
Flumadine
(Rimantadine)

**ENDO
PHARMACEUTICALS**
Symmetrel
(Amantadine)

NAIs
Inavir
Laninamivir
(Japan only)

BioCryst SHIONOGI
Rapivab
peramivir

ADAMAS
TCAD
Combo

**THERACLONE
SCIENCES**
TCN-032
mAb M2e

Visterra
VIS-410
mAb

emergent
IVlg
H1N1/H3N2

janssen
Pimodivir
PB2 inhibitor

PA Inhibitor
Roche SHIONOGI
Xofluza
Baloxavir

gsk GlaxoSmithKline
Relenza
zanamivir

Roche
Tamiflu
oseltamivir

Gemmus PHARMA
GP1001
(ImmMod)

pulmatrix
PUR003

**Karyopharm
Therapeutics**
Verdinexor

**HEMISPHER
BIOPHARMA, INC.**
Alferon LDO
INF- α 3

**Beth Israel Deaconess
Medical Center**
Atorvastatin

**Centre Hospitalier Regional
de l'Acadie**
Etilefrine
Diltiazem

ANSUN
FLUDASE

XC221

The University of Hong Kong
Celecoxi
b

**Romark
Laboratories, L.C.**
Nitazoxanide

Other
Inhaled
IV
Oral